Latest news and research on all cancers and treatments, updated several times a week
Pancreatic Cancer: 20. American Journal of Cancer. Determined cannabinoid induced apoptosis, reduced the growth of tumor cells, and inhibited the ...
Research published in the journal Lancet Oncology show that increased levels of colon, kidney, and pancreatic cancer are directly caused by obesity.
Endocrine Agent Makes Mark in Breast Cancer
Fulvestrant regimens improve outcomes in advanced disease.Full story
Fulvestrant regimens improve outcomes in advanced disease.Full story
Results in women with HER2-positive disease fall short, but a subset of patients see some survival benefit. Full story
Now a new study shows that the shape of an antibody can make a big difference to the effectiveness of so-called cancer immunotherapy.
"We are learning that there are few treatments that don't have some footprint in the cancer genome," said lead researcher Timothy Chan, MD, PhD, ...
Ramucirumab-Docetaxel Approved for Advanced NSCLC
The FDA has approved the combination of ramucirumab and docetaxel for the treatment of patients with metastatic non-small-cell lung cancer.
The FDA has approved the combination of ramucirumab and docetaxel for the treatment of patients with metastatic non-small-cell lung cancer.
Million-Person Study Shows No Link Between Pioglitazone and Bladder Cancer
An extremely large database study across more than one million people found no increased risk of bladder cancer with the diabetes drug pioglitazone.
An extremely large database study across more than one million people found no increased risk of bladder cancer with the diabetes drug pioglitazone.
Aromatase Inhibitor Side Effects No Surrogate for Efficacy in Breast Cancer
A large trial showed that treatment-emergent vasomotor and/or joint symptoms do not correlate with any improvement in recurrence-free survival in postmenopausal breast cancer patients treated with aromatase inhibitors.
A large trial showed that treatment-emergent vasomotor and/or joint symptoms do not correlate with any improvement in recurrence-free survival in postmenopausal breast cancer patients treated with aromatase inhibitors.
Two Regimens Yield Similar Survival in Advanced NSCLC
An analysis showed that etoposide-cisplatin or carboplatin-paclitaxel with RT yielded similar survival in patients with stage III non-small-cell lung cancer.
An analysis showed that etoposide-cisplatin or carboplatin-paclitaxel with RT yielded similar survival in patients with stage III non-small-cell lung cancer.
Daratumumab Safe With Myeloma Backbone Therapies
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.
2014 SABCS
Partial Breast Irradiation Sufficient in Early Disease
Accelerated partial breast irradiation was shown to be just as effective and safe as whole breast irradiation in early-stage breast cancer patients.
Accelerated partial breast irradiation was shown to be just as effective and safe as whole breast irradiation in early-stage breast cancer patients.
Preventive Tamoxifen Lowers Rate of ER-Positive Breast Cancer
Tamoxifen given to women at high risk for breast cancer lowered the rate of estrogen receptor (ER)-positive breast cancer diagnosis in the IBIS-I trial.
Tamoxifen given to women at high risk for breast cancer lowered the rate of estrogen receptor (ER)-positive breast cancer diagnosis in the IBIS-I trial.
Fulvestrant Improved Survival in First-Line Advanced Breast Cancer
Fulvestrant improved overall survival compared with anastrozole, among women with treatment-naive, advanced, hormone receptor-positive breast cancer.
Fulvestrant improved overall survival compared with anastrozole, among women with treatment-naive, advanced, hormone receptor-positive breast cancer.
Decreased Fat Intake May Improve Survival in Some Breast Cancers
Data from the Women's Intervention Nutrition Study found a reduction in dietary fat intake resulted in lower death rates in ER- and PR-negative breast cancer.
Data from the Women's Intervention Nutrition Study found a reduction in dietary fat intake resulted in lower death rates in ER- and PR-negative breast cancer.
PI3K Inhibitor in ER-Positive Breast Cancer Shows Activity
Results of a phase II study of a PI3K inhibitor in ER-positive breast cancer showed a trend toward improved progression-free survival.
Results of a phase II study of a PI3K inhibitor in ER-positive breast cancer showed a trend toward improved progression-free survival.
Marker in HER2-Positive Breast Cancer Linked to Chemo Benefit
The level of stromal tumor-infiltrating lymphocytes (Str-TILs) may influence which treatment is the most effective in women with HER2-positive breast cancer.
The level of stromal tumor-infiltrating lymphocytes (Str-TILs) may influence which treatment is the most effective in women with HER2-positive breast cancer.
Capecitabine Ineffective in Elderly Early Breast Cancer Patients
The use of adjuvant capecitabine in elderly patients with moderate- to high-risk early breast cancer resulted in no improvement in disease-free survival.
The use of adjuvant capecitabine in elderly patients with moderate- to high-risk early breast cancer resulted in no improvement in disease-free survival.
Ovarian Suppression Benefits Young Breast Cancer Patients
Early-stage premenopausal ER-positive breast cancer patients who have received chemotherapy benefited from ovarian suppression with tamoxifen or exemestane.
Early-stage premenopausal ER-positive breast cancer patients who have received chemotherapy benefited from ovarian suppression with tamoxifen or exemestane.
Immunotherapy Yields Response in Triple-Negative Breast Cancer
The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.
The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.
Avastin May Benefit Basal-Like Breast Cancer Patients
A study of triple-negative breast cancer patients found that adding bevacizumab (Avastin) to chemo resulted in higher pCR rates in those with basal-like disease.
A study of triple-negative breast cancer patients found that adding bevacizumab (Avastin) to chemo resulted in higher pCR rates in those with basal-like disease.
Cancer News in Science Daily
Survey of the general population in France identifies knowledge gaps in the perception of lung cancer
“A prospective nationwide survey on perceptions of lung cancer in the general population of France highlights a need for increased public education on the benefits of lung cancer screening, the good survival rates of early-stage disease and the improved outcomes with new therapeutic strategies, including targeted-therapies.
Targeted next-generation sequencing reveals a high number of genomic mutations in advanced malignant
“Next generation sequencing in malignant pleural mesothelioma tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival.
“A lens-free microscope that can be used to detect the presence of cancer or other cell-level abnormalities with the same accuracy as larger and more expensive optical microscopes, has been developed by researchers. The invention could lead to less expensive and more portable technology for performing common examinations of tissue, blood and other biomedical specimens. It may prove especially useful in remote areas and in cases where large numbers of samples need to be examined quickly.
“More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other areas of the body. A new study has identified how one important gene helps cancer cells break free from the primary tumor.
“Two related proteins exert a lethal double whammy effect against glioblastoma cells when activated with a small molecule. Scientists say when activated, one protein, called the short form, stops glioblastoma cells from replicating their DNA, and the other, called the long form, prevents cell division if the DNA has already been replicated.
“Loss of a gene called PTEN triggers some cases of an aggressive form of ovarian cancer, called high-grade serous ovarian cancer, researchers have demonstrated. In a revolutionary approach, the researchers made the discovery by combining images from cancer samples with genetic data. They proved conclusively that loss of PTEN was commonly found only in the cancerous cells and not the 'normal' cells that help make up the tumour mass.
Tambahkan Komentar